Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026)
Rapport Therapeutics (RAPP) reported Cash from Financing Activities of $531000.0 for Q1 2026, up 10520.0% year-over-year from N/an in Q1 2025, and up 70.74% quarter-over-quarter from $311000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Cash from Financing Activities data on file, last reported at $531000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $531000.0, up 10520.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $271.3 million (up 71.75% YoY), and the FY2025 annual result was $270.8 million, up 22.18% from the prior year.
- Cash from Financing Activities climbed to $531000.0 in Q1 2026 per RAPP's latest filing, from $311000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $270.5 million in Q3 2025 and troughed at -$1.4 million in Q3 2024.
- A 4-year average of $52.6 million and a median of $311000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 101.63% in 2024, then surged 19506.96% in 2025.
- A 4-year view of Cash from Financing Activities shows it stood at -$140000.0 in 2023, then soared by 105.0% to $7000.0 in 2024, then jumped by 4342.86% to $311000.0 in 2025, then surged by 70.74% to $531000.0 in 2026.
- Business Quant data shows RAPP's Cash from Financing Activities at $531000.0 in Q1 2026, $311000.0 in Q4 2025, and $270.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | 531,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 531,000.00 |
| Mar 31, 2026 | 531,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 270.53 Mn |
| Sep 30, 2025 | 270.53 Mn |
| Jun 30, 2025 | -63,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | -1.39 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Jun 30, 2024 | 159.35 Mn |
| Mar 31, 2024 | 63.66 Mn |
| Mar 31, 2024 | 63.66 Mn |
| Dec 31, 2023 | -140,000.00 |
| Dec 31, 2023 | -140,000.00 |